Biotech Values

[masterlongevity]

When i read the results in Lancet, I have to disagree.

THe dimebon treated patients showed a 6 point advantage on the ADAS-CoG vs. about 2-3 points seen from historical aricept trials. The dimebon results were clearly better. i have spoken to many of the KOLs in Neurology and they are very excited for the 6 month results. I do agree with you that 1yr resutls will be very interesting as they may for the 1st time show disease modification.